Compare IMMR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | CABA |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.4M | 227.2M |
| IPO Year | 1999 | 2019 |
| Metric | IMMR | CABA |
|---|---|---|
| Price | $6.44 | $2.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $12.25 | ★ $13.50 |
| AVG Volume (30 Days) | 689.7K | ★ 2.2M |
| Earning Date | 12-19-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | ★ 57.07 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $163,133,000.00 | N/A |
| Revenue This Year | $988.71 | N/A |
| Revenue Next Year | $109.72 | N/A |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | ★ 338.21 | N/A |
| 52 Week Low | $5.65 | $0.99 |
| 52 Week High | $9.37 | $3.67 |
| Indicator | IMMR | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 48.61 |
| Support Level | $6.42 | $2.32 |
| Resistance Level | $7.09 | $2.48 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 6.16 | 17.50 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.